Insider Purchases: Inside the Buy

Tag: Rare diseases

Colorful illustration of Biohaven’s CEO and directors dropping glowing dollar bills into a three-chamber biotech machine labeled ‘Epilepsy,’ ‘Obesity,’ and ‘IgA Nephropathy,’ while an FDA storm cloud hovers overhead but an angel floats above the pipeline.

Biohaven Just Went Through Hell — But Its CEO and Directors Still See an Angel

Biohaven’s stock plunged after a brutal FDA rejection — but insiders didn’t blink. They bought millions of dollars’ worth of shares, doubled down on their pipeline, and kickstarted a leaner, more focused strategy. Bold turnaround play or biotech heartburn waiting to happen? Here's the FUNanc1al deep dive.

Read entire article

Tags: BHVN, Biohaven, Biotech Investing, Biotech Stocks, buy or sell bhvn, CEO Buys, CEO Conviction, CEO insider buying, CEO Insider Purchases, CEO Stock Purchase, CEOBuyIn, Clinical Trials, Dr. Vlad Coric, fda news, funanc1al, funanc1al humor, immunology, insider buying, neuroscience, rare diseases, risks investing in bhvn, speculative stocks, why invest in bhvn
A vibrant infographic showing a DNA double helix, syringes, a downward-sloping stock chart turning upward, and a confident CEO dropping a golden coin into the Moderna logo, labeled “$5M Insider Buy”

Moderna: Messenger RNA Medicines Powerhouse Sends A New Message — “Discount!”

Insiders dropped $6M on Moderna stock. With a massive mRNA pipeline and deep-pocketed backers, is this biotech beast ready to roar again?

Read entire article

Tags: Baillie Gifford, Biotech Stocks, Cash Burn, CEO insider buying, Checkpoint Immunotherapy, COVID, Cytomegalovirus, Director Insider Buying, Finance with Fun, Funanc1al Insider Series, Funanc1alInsiderSeries, Healthcare Innovation, insider buying, Insider Buys, Insider Purchases, InsiderActivity, InsiderBuying, InsiderPurchases, InsiderScoops, Investment Ideas, Moderna, MRNA, MRNA Stock, Norovirus, Oncology, Pharma, R&D, Rare diseases, RSV, Stock Market, Vaccine Stocks, Valuation Biotech, Wall Street